Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 2,413 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Laboratory testing Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effect of Lycopene and Isoflavones on Glucose Metabolism

NCT01377961
View directory record Official record
Conditions
Metabolic Syndrome, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks, Screening, OGTT, Anthropometrics and Blood pressure, Blood Drawing
Drug · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 27, 2026, 10:38 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Project Wellness: Increasing HIV Testing Among West African Immigrants

NCT01270061
View directory record Official record
Conditions
Diabetes, Hypertension, HIV
Interventions
HIV testing, General Health Screen
Behavioral
Lead sponsor
North Bronx Healthcare Network
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 27, 2026, 10:38 PM EDT
Recruiting Phase 2 Interventional

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

NCT07003295
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Glofitamab, Obinutuzumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Duarte, California • Atlanta, Georgia • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Not applicable Interventional Results available

Study of an Investigational Glucose Meter System

NCT01466075
View directory record Official record
Conditions
Diabetes
Interventions
Apollo Evolution Investigational BG Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Mishawaka, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 27, 2026, 10:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

NCT07083557
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions
Endothelial cell collection
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Impact of Insomnia on Pain in HIV

NCT04298658
View directory record Official record
Conditions
HIV, Insomnia
Interventions
Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised, Resmed ApneaLink Air device (Resmed, San Diego, CA)., Quantitative Sensory testing (QST), OraQuick Advance Rapid HIV 1/2 Swab test, Cluster of Differentiation 4 (CD4) and Viral load
Diagnostic Test · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Not applicable Interventional

Pre-exposure Prophylaxis (PrEP) Rapid Access

NCT05528562
View directory record Official record
Conditions
Drug Use, Pre-exposure Prophylaxis (PrEP), Opioid Use Disorder
Interventions
PrEP Rapid Access, HIV self-testing, Dried blood spot testing
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 27, 2026, 10:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents

NCT05437588
View directory record Official record
Conditions
Major Depressive Disorder, Suicidal Ideas, Suicide, Attempted, MDD, Depression, Depression, Teen, Depression and Suicide, Depression in Adolescence, Suicide
Interventions
Genetic testing
Genetic
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 24 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Recruiting No phase listed Observational

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

NCT04541654
View directory record Official record
Conditions
Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis, Mosaicism
Interventions
Data and Specimen Collection
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Not yet recruiting Not applicable Interventional

Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients

NCT06744712
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Pharmacogenomic Testing
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 26 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology

NCT03167996
View directory record Official record
Conditions
Cardiovascular Risk Factor, Insulin Resistance, PreDiabetes, Diabetes, Coronary Artery Disease, Hypertension, Prehypertension, Dyslipidemias
Interventions
Use of HealthPals (Telemedicine supported by digital health platform)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 27, 2026, 10:38 PM EDT
Active, not recruiting Phase 2 Interventional

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

NCT04334941
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
561
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

NCT05550337
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
14
States / cities
West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 27, 2026, 10:38 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

NCT06357975
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Crizotinib, Radiologic Examination
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

NCT05987241
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
495
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 374 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Consumer Use of a New Home Test to Measure Sperm Concentration

NCT02475395
View directory record Official record
Conditions
Fertility, Male, Sub-Fertility, Male
Interventions
TRAK device
Device
Lead sponsor
Sandstone Diagnostics
Industry
Eligibility
20 Years to 50 Years
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Encino, California • Tarzana, California • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 27, 2026, 10:38 PM EDT
Not yet recruiting Phase 1 Interventional

BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

NCT07583303
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine, Leukapheresis, Single Agent Therapy
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Recruiting Not applicable Interventional

Atlantic Lipid Lowering Treatment Optimization Program

NCT06439654
View directory record Official record
Conditions
Familial Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Apolipoprotein B 100, Familial Defective, High Density Lipoprotein Deficiency, Low-Density-Lipoid-Type Hyperlipoproteinemia
Interventions
Supportive care
Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Clark, New Jersey • Springfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 27, 2026, 10:38 PM EDT
Terminated No phase listed Observational

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

NCT04600466
View directory record Official record
Conditions
Gastric Cancer
Interventions
Molecular testing for all participants., Germline Testing, Survey
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Recruiting No phase listed Observational

Genomic Analysis of Families With a History of Discordant Cancers

NCT04860453
View directory record Official record
Conditions
Discordant Cancers
Interventions
WES via Illumina NextSeq 550 sequencing system, Blood Draw, Skin biopsy, Saliva Sample
Genetic · Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Not applicable Interventional

Text Messages for Liver Transplant Recipients

NCT04995770
View directory record Official record
Conditions
Medication Adherence, Liver Transplant Disorder
Interventions
Praise Text Messages
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
13 Years to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 27, 2026, 10:38 PM EDT
Recruiting Not applicable Interventional

ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

NCT07270666
View directory record Official record
Conditions
Endometrial Cancer
Interventions
ctDNA Testing, Blood draw, Surveys, Semi-structured interviews
Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Suspended Phase 1Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

NCT06620302
View directory record Official record
Conditions
Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Fibrolamellar Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Childhood Fibrolamellar Carcinoma, Refractory Childhood Malignant Solid Neoplasm, Refractory Fibrolamellar Carcinoma, Refractory Malignant Solid Neoplasm
Interventions
Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan
Biological · Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 39 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1

NCT07015437
View directory record Official record
Conditions
Healthy Subjects
Interventions
INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs
Device · Other
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 27, 2026, 10:38 PM EDT